Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production
http://www.100md.com
动脉硬化血栓血管生物学 2005年第3期
From the Department of Medicine (J.S.M., C.M., D.M.K., E.C.B., J.M.W., D.J.R.), University of Pennsylvania, Philadelphia; the Division of Cardiology (K.I., S.M.), Department of Internal Medicine and the Department of General Medicine (N.T.), Kashiwa Hospital, Jikei University School of Medicine, Tokyo, Japan; the School of Medicine and Pharmacology (P.H.R.B.), University of Western Australia, Perth; the Biomathematics Unit (R.C.B.), University of Pennsylvania School of Veterinary Medicine, Kennett Square; and the Department of Vascular Medicine (J.C.D.), Academic Medical Center at the University of Amsterdam, the Netherlands.
Correspondence to John S. Millar, PhD, University of Pennsylvania, 644 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104. E-mail jsmillar@mail.med.upenn.edu
Abstract
Objective— We addressed the role of the low-density lipoprotein (LDL) receptor in determining clearance rates and production rate (PR) of apolipoprotein B (apoB) in humans.
Methods and Results— Kinetic studies using endogenous labeling of apoB with deuterated leucine were performed in 7 genetically defined patients with homozygous familial hypercholesterolemia (FH) and compared with 4 controls. The fractional catabolic rates (FCR) and PRs for apoB were determined by multicompartmental modeling. The FCRs of very-low-density lipoprotein 1 (VLDL1), VLDL2, intermediate-density lipoprotein (IDL), and LDL apoB were lower in FH than in controls, with the LDL apoB FCR being significantly lower (0.148±0.049 versus 0.499±0.099 pools · d–1; P=0.008). Whereas receptor-defective FH patients had a total apoB PR similar to controls, receptor-null FH patients had a significantly greater total apoB PR than controls (35.97±10.51 versus 21.32±4.21 mg · kg–1 · d–1, respectively; P=0.02).
Conclusions— This first study of apoB metabolism in homozygous FH using endogenous labeling with stable isotopes demonstrates that the LDL receptor contributes significantly to the clearance of LDL from plasma but plays a lesser role in the clearance of larger apoB-containing lipoproteins. Furthermore, these data also indicate that absence of a LDL receptor in humans substantially influences the apoB PR in vivo.
Kinetic studies on apoB were conducted in genetically defined patients with homozygous FH. FH patients had significantly decreased clearance of LDL apoB. Receptor-null FH had a significantly increased apoB production. We conclude that the LDL receptor primarily mediates clearance of LDL apoB from plasma and can influence apoB production in vivo.
Key Words: cholesterol ? familial hypercholesterolemia ? VLDL ? LDL ? apoB
Introduction
The low-density lipoprotein (LDL) receptor is best known for its role in mediating the hepatic uptake of LDL from plasma.1 Mutations in the LDL receptor frequently result in familial hypercholesterolemia (FH), a disorder associated with hypercholesterolemia and premature atherosclerosis.1 Whereas patients with FH have elevations in LDL cholesterol levels, plasma triglyceride levels are generally normal,1 suggesting that other mechanisms clear the majority of triglyceride-rich very-low-density lipoprotein (VLDL) and VLDL remnants. Previous studies conducted using lipoproteins exogenously labeled with radiotracers have demonstrated a slower fractional catabolic rate (FCR) of intermediate-density lipoprotein (IDL) and LDL apolipoprotein (apoB), but not VLDL apoB, in homozygous FH patients.2,3
In addition to the role of mediating clearance of apoB-containing lipoproteins, a role for the LDL receptor in regulating the hepatic production rate (PR) of VLDL apoB has been proposed.4,5 Williams et al4 observed that blocking LDL receptor on the surface of the HepG2 cells affected apoB secretion. This led them to conclude that there can be reuptake of newly secreted apoB from hepatocytes by the LDL receptor. Twisk et al5 studied apoB secretion in vitro using primary hepatocyte cultures from Ldlr–/– and wild-type mice. They found that hepatocytes from Ldlr–/– mice had reduced intracellular degradation resulting in an increased PR of apoB, which led to their hypothesis that the LDL receptor targets apoB for degradation within the secretory pathway.5
In vivo studies using the Watanabe heritable hyperlipidemic (WHHL) rabbit showed no effect of LDL receptor deficiency on VLDL production.6 However, the WHHL rabbit has defective LDL receptors7 that can potentially influence apoB production.5 We measured apoB production in Ldlr–/– mice and found that despite having a complete absence of LDL receptors, the apoB PR in these animals was similar to wild-type mice.8 Kinetic studies of apoB in homozygous FH patients conducted using radiolabeled lipoproteins have not conclusively established whether deficiency of LDL receptors influences apoB production in humans.2,3
In the current study, we used an endogenous labeling approach with a stable isotope tracer to study the metabolism of apoB in vivo in homozygous FH subjects. The results indicate that in patients lacking a functional LDL receptor, the PR of apoB is significantly increased.
Methods
Subjects
Seven homozygous FH patients were recruited from a cohort followed at the University of Pennsylvania. Four healthy individuals were recruited to act as control subjects. All patients and subjects were nonsmokers with normal hepatic, renal, and thyroid function. Control subjects were not using any medications known to affect plasma lipid levels. FH patients stopped all lipid-lowering treatments 4 weeks before the kinetic studies. The protocol was approved by the Human Investigational Review Board of the University of Pennsylvania. All subjects gave informed consent.
DNA Analysis
Genomic DNA was prepared from peripheral blood leukocytes.9 For denaturing gradient gel electrophoresis analysis,10 the promoter region11 and all 18 exons of the LDL receptor, including the exon–intron boundaries,10,12 were individually amplified from genomic DNA by polymerase chain reaction using TaqDNA polymerase (Qiagen, Germany).
Fragments showing an aberrant pattern of bands, suggestive of a sequence variation, were separately amplified by polymerase chain reaction using the same oligonucleotide primer pairs as used for denaturing gradient gel electrophoresis. The sequence reactions were performed using fluorescently labeled dideoxy chain terminations with the Big Dye Terminator ABI Prism Kit (Applied Biosystems) and analyzed on the Applied Biosystems Model 310 automated DNA sequencer. For confirmation of the sequence variant in other patients, a polymerase chain reaction protocol followed by restriction endonuclease digestion was designed.
Infusion Protocol
Subjects were admitted to the General Clinical Research Center of the Hospital of the University of Pennsylvania. After an overnight fast, subjects consumed the first of 10 bi-hourly solid meals representing one-tenth of the daily caloric intake containing <10% fat. One hour after the first meal, subjects were given a bolus injection (20 μmol · kg–1) of [2H3]-leucine immediately followed by a 12-hour constant infusion of [2H3]-leucine (20 μmol · kg–1 · h–1). Blood samples were drawn periodically for 96 hours after the bolus injection.
Plasma Lipids and Lipoprotein Fraction Preparation
Blood was collected in tubes containing EDTA. Plasma was separated by centrifugation and preservatives added. VLDL1, VLDL2, IDL, and LDL were isolated by ultracentrifugation.13 Plasma total cholesterol, high-density lipoprotein, and triglyceride concentrations were determined using enzymatic reagents (Wako Chemicals USA, Richmond, Va).
Isolation and Quantification of Apolipoproteins
ApoB was isolated from the lipoprotein fractions by isopropanol precipitation, norleucine added as an internal standard, followed by hydrolysis with 6 mol/L HCl at 100°C for 24 hours.14 Under the study dietary conditions there was a negligible contribution of apoB48 (<4%) to the precipitated apoB in the VLDL1 and VLDL2 fractions. ApoE phenotypes were determined on neuraminidase-treated plasma using the method of Havekes et al.15
Determination of Isotopic Enrichment
Free amino acids were isolated from apoB protein hydrolysates by cation exchange chromatography followed by derivatization and determination of tracer/tracee ratio using gas chromatography/mass spectrometry as described.16
Plasma apoB concentrations were measured using an immunoturbidimetric assay (Wako Chemicals USA). The apoB concentration within each lipoprotein fraction was calculated from the apoB leucine content of that fraction, relative to the norleucine internal standard,17 and adjusted to reflect the proportion of total apoB.
Kinetic Analysis
ApoB metabolic parameters (PR and FCR) were calculated from apoB tracer/tracee ratios using 2 independent compartmental models. The first analysis used a previously described model18 with a total VLDL tracer/tracee data set created by taking the weighted mean of the VLDL1 and VLDL2 tracer/tracee data. A confirmatory analysis was conducted19 using the model shown in Figure 1. Both analyses provided similar results. The data included in the manuscript are from the latter analysis. Model calculated pool sizes were within 5% of measured pool size (average of 6 apoB measurements taken over the course of the 96-hour study period).
Figure 1. The multicompartmental model used in the analysis of the deuterated leucine tracer kinetic data.
VLDL1 and VLDL2 kinetic parameters for FH1 were fixed to the average values of the remaining 6 FH patients because of the low concentration of VLDL1, and hence poor tracer data in this subject. Subject C4 had an LDL apoB pool with a rapid turnover (10% of the total LDL pool). To reduce complexity, this portion of the kinetic curve was unweighed.
Statistical Analysis
Statistical comparisons between study groups were made with a Wilcoxon rank sum test. Probability values <0.05 were considered statistically significant.
Results
The subject characteristics at the time of the kinetic study are shown in Table 1. The FH patient group contained 4 males and 3 females and the control group consisted of 2 males and 2 females. All patients and controls displayed an apoE3/3 phenotype. At the time of the kinetic study, the FH patients had significantly higher total cholesterol levels (511±100 versus 128±14 mg · dL–1; P<0.008) and significantly lower high-density lipoprotein cholesterol levels (26±9 versus 42±3 mg · dL–1; P<0.023) than controls, whereas plasma triglyceride levels were similar between the 2 groups (114±74 versus 73±22 mg · dL–; P=0.26). Patient FH6 was hypertriglyceridemic whereas the remaining FH patients were normotriglyceridemic.
TABLE 1. Subject Characteristics at the Time of the Kinetic Study
Representative tracer/tracee ratio curves for the FH and control groups are shown in Figures 2 and 3. The calculated pool sizes within each fraction are shown in Table 2. The VLDL1 and VLDL2 apoB pool sizes in FH patients were similar to controls (1.55±1.95 versus 0.68±0.42 mg · kg–1; P=0.45; 1.80±2.26 versus 0.68±0.22 mg · kg–1; P=0.19, respectively), whereas the IDL and LDL apoB pool sizes were increased in the FH patients (3.85±4.21 versus 1.15±0.25 mg · kg–1; P=0.02; 98.12±16.12 versus 24.79±5.44 mg · kg–1; P<0.001). When the hypertriglyceridemic patient, FH6, was excluded, the VLDL1 apoB pool size was similar to controls (0.83±0.46 versus 0.68±0.42 mg · kg–1; P=0.25), whereas VLDL2, IDL, and LDL apoB pool sizes were significantly larger than those of the controls (0.96±0.31 versus 0.68±0.22 mg · kg–1; P=0.02; 2.27±0.62 versus 1.15±0.25 mg · kg–1; P=0.02; 98.94±17.5 versus 24.79±5.44 mg · kg–1; P<0.02, respectively). Please see http://atvb.ahajournals.org for the apoB concentrations of each fraction.
Figure 2. Representative tracer kinetic data for the VLDL1 and VLDL2 lipoprotein fractions in control subject C3 and FH patient FH7. The model-derived fit to the data (solid triangles) is shown as a solid line.
Figure 3. Representative tracer kinetic data for the IDL and LDL lipoprotein fractions in control subject C3 and FH patient FH7. The model-derived fit to the data (solid triangles) is shown as a solid line.
TABLE 2. Calculated apoB Pool Size and FCR for Each Lipoprotein Fraction
The FCRs for apoB within each lipoprotein fraction are shown in Table 2. As expected, the FCR of LDL apoB was markedly slower in the FH patients compared with the controls (0.148±0.049 versus 0.499±0.099 pools · d–1; P=0.008). Although not significant, the FH patients also had slower FCRs for VLDL1 (7.02±2.78 versus 10.29±4.92 pools · d–1; P=0.19), VLDL2 (12.64±7.19 versus 16.94±5.98 pools · d–1; P=0.57), and IDL (9.56±9.10 versus 12.17±1.92 pools · d–1; P=0.26) apoB.
There were no significant differences between FH patients and controls in the direct PRs of VLDL1, VLDL2, IDL, or LDL apoB (Table 3). There were also no significant differences in the total PRs (direct hepatic production plus conversion from other fractions) of apoB in any lipoprotein fraction or conversion rates of apoB between lipoprotein fractions. There was a nonsignificant trend toward an increased total apoB PR in FH patients compared with controls (32.11±10.44 versus 21.32±4.21 mg · kg–1 · d–1; P=0.06).
TABLE 3. Production and Conversion Rates of apoB From Each Lipoprotein Fraction
Three of the FH patients were receptor-defective and therefore expressed partially functional LDL receptor. A subgroup analysis was conducted in the 4 LDL receptor-null patients with the FH Lebanese mutation (C660X). This mutation produces a truncated receptor that is not fully processed and is degraded before reaching the cell surface,20 resulting in a LDL receptor-null phenotype. A subanalysis comparing receptor-null FH patients to controls showed that these patients had significantly increased total VLDL2 and IDL apoB PRs than control subjects (20.42±6.44 versus 12.10±1.56 mg · kg–1 · d–1; P=0.02; 21.44±8.21 versus 13.69±1.51 mg · kg–1 · d–1; P=0.04, respectively) and greater total apoB PRs than controls (35.97±10.51 versus 21.32±4.21 mg · kg–1 · d–1; P=0.02). FH patients that have expression of partially functional LDL receptors or low-level expression of fully functional LDL receptors had total apoB PRs that were similar to controls (25.85±7.72 versus 21.32±4.21 mg · kg–1 · d–1, receptor-defective FH versus control, respectively, P=0.48).
Discussion
This report of apoB kinetics using endogenous labeling with stable isotopes confirms that LDL apoB clearance is markedly decreased in homozygous FH patients. It also establishes that homozygous FH patients with mutations resulting in a complete absence of the LDL receptor have an increased apoB PR, supporting predictions based on in vitro studies.
An important aspect of this study is that all FH patients were characterized for their LDL receptor mutations at the molecular level. Three of the 7 FH patients (FH1 to FH3) had receptor-defective mutations that either resulted in reduced levels of functional receptor (FH1)21,22 or affected ligand binding (FH2, FH3).23–25 Four patients (FH4-FH7) were homozygous for the FH Lebanese mutation.20 This mutation results in transcription of a truncated receptor that not fully processed and is retained in the endoplasmic reticulum (ER),20 resulting in a receptor-null phenotype.
Although FH patients have elevated total cholesterol levels, plasma triglyceride levels are frequently normal suggesting less of a role for the LDL receptor in the clearance of triglyceride-rich lipoproteins. Although VLDL clearance can be enhanced in Ldlr–/– mice through overexpression of the LDL receptor,26 the extent to which VLDL and IDL apoB are cleared from plasma by LDL receptors in vivo in humans is not established. Packard et al27 found that modification of the LDL receptor binding region of apoB had no effect on VLDL clearance but reduced clearance of IDL in normal subjects. Using radiolabeled lipoproteins, James et al2 found VLDL1 and VLDL2 clearance in homozygous FH to be similar to control subjects whereas the FCR of IDL apoB was significantly slower than controls. Soutar et al3 also observed slower clearance of IDL apoB in homozygous FH. In the current study, using endogenous labeling, we observed slower, but not significant, clearance of IDL apoB in FH patients. The FCRs of VLDL1 and VLDL2 apoB were not significantly different between FH patients and controls indicating a minor role of the LDL receptor in the clearance of these lipoproteins.
The role of the LDL receptor in regulating apoB production was first highlighted in in vitro studies by Williams et al.4 They noted an increased secretion of apoB from hepatocytes in which the LDL receptor was blocked to prevent lipoprotein uptake. Twisk et al5 found increased secretion of apoB by primary hepatocytes from Ldlr–/– mice when compared with wild-type mice. Analysis of the tracer data suggested that this was caused by reduced presecretory degradation of apoB and reduced capture of newly secreted VLDL. This led to their hypothesis that the LDL receptor may bind apoB intracellularly and target it for degradation. In vivo studies in the WHHL rabbit6 and Ldlr–/– mice8 showed no differences in the PR of VLDL triglyceride or apoB when compared with Ldlr+/+ control animals. Whereas the WHHL rabbit is considered receptor-defective and may be capable of targeting newly synthesized apoB for degradation, the same cannot be said for Ldlr–/– mice that are receptor-null. The discrepancy observed between in vivo and in vitro studies in mice may be caused by differential changes in expression of genes involved in VLDL secretion by wild-type and Ldlr–/– primary hepatocytes after several hours in culture, although this remains to be tested.
Human kinetic studies using exogenously radiolabeled lipoproteins in patients with homozygous FH have not shown consistent differences with control subjects in the apoB PR.2,3 A report by Soutar et al3 found that VLDL apoB PRs among uncharacterized FH homozygotes, heterozygotes, and normal control subjects were similar. Subsequently, James et al2 reported that homozygous FH patients had significantly greater (>60%) apoB PRs as compared with control subjects. Despite this increased PR in the total group of FH homozygotes, those patients with <10% LDL receptor activity had total apoB PRs that were similar to those for control subjects. In the current study, we used endogenous labeling of apoB and also characterized the precise molecular defects in the LDL receptor gene. We found that the total apoB PR in the homozygous FH patients trended higher than control subjects but was not statistically significant. A subgroup analysis comparing patients with an LDL receptor-null phenotype and control subjects demonstrated that the apoB PR was significantly elevated in the receptor-null FH patients. One receptor-null patient (FH6) had elevated plasma triglyceride levels that could potentially result from increased VLDL production. The kinetic analysis revealed that the raised plasma triglyceride level was primarily caused by reduced clearance of VLDL apoB. Despite the metabolic heterogeneity of this receptor-null subgroup, the overall elevated PR measured is consistent with the increased PR measured by Tremblay et al28 in a single receptor-null homozygote. This result supports a role for the LDL receptor in regulating the presecretory degradation of apoB in vivo in humans.
An alternative explanation for increased apoB production in receptor-null FH patients is unregulated hepatic lipid synthesis resulting from the lack of exogenous cholesterol uptake.29 Homozygous FH patients with a portacaval shunt have a relatively low total apoB PR.2 Portacaval shunting has been reported to reduce hepatic lipid synthesis30 and therefore support this alternative explanation. Unregulated hepatic lipid synthesis could also explain the increased apoB production observed in some studies in heterozygous FH.28,31 A recent report indicates that heterozygous FH patients with a receptor-null allele have been shown to have increased apoB production.28 Further studies in FH patients with other receptor-null mutations would be required to determine whether this is a generalized or mutation-specific effect.
In summary, this first study of apoB metabolism in a group of genetically defined homozygous FH patients confirmed a major role for the LDL receptor in the clearance of LDL, but not VLDL or IDL. More importantly, the total apoB PR was significantly increased in receptor-null FH homozygotes. These studies indicate that the LDL receptor plays a major role in the clearance of cholesterol-rich apoB-containing lipoproteins and may also function in modulating the PR of apoB in vivo in humans.
Acknowledgments
Supported by grant M01-RR00040 from the National Center for Research Resources to the University of Pennsylvania General Clinical Research Center, NRSA HL-10365 (J.S.M.), and funds from Genovo, Inc. D.J.R. is a recipient of a Doris Duke Distinguished Clinical Investigator Award. P.H.R.B. is a fellow of the National Health and Medical Research Council of Australia and is partly supported by NIH/NIBIB grant P41 EB-009175. We thank Anna DiFlorio and Linda Morrell for lipid analyses and the nursing staff of the General Clinical Research Center for their assistance. We also thank the patients whose participation and cooperation made these studies possible.
References
Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beauder AL, Sly WS, Valle D, eds The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill; 1995: 1981–2030.
James RW, Martin B, Pometta D, Fruchart JC, Duriez P, Puchois P, Farriaux JP, Tacquet A, Demant T, Clegg RJ. el al. Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res. 1989; 30: 159–169.
Soutar AK, Myant NB, Thompson GR. The metabolism of very low density and intermediate density lipoproteins in patients with familial hypercholesterolaemia. Atherosclerosis. 1982; 43: 217–231.
Williams KJ, Brocia RW, Fisher EA. The unstirred water layer as a site of control of apolipoprotein B secretion. J Biol Chem. 1990; 265: 16741–16744.
Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PHR, Attie AD. The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest. 2000; 105: 521–532.
Hornick CA, Kita T, Hamilton RL, Kane JP, Havel RJ. Secretion of lipoprotein from the liver of normal and Watanabe heritable hyperlipidemic rabbits. Proc Natl Acad Sci, U S A. 1983; 80: 6096–6100.
Yamamoto T, Bishop RW, Brown MS, Goldstein JL, Russell DW. Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. Science. 1986; 1232: 1230–1237.
Millar JS, Maugeais C, Fuki IV, Rader DJ. Normal production rate of apoB in LDL receptor deficient mice. Arterioscler Thromb Vasc Biol. 2002; 22: 989–994.
Mullenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet. 1989; 5: 391.
Khoo KL, Van Acker P, Defesche JC, Tan H, Van de Kerkhof L, Heijnen-van Eijk SJ, Kastelein JJP, Deslypere JP. Low-density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia. Clin Genet. 2000; 58: 98–105.
Nissen H, Guldberg P, Hansen AB, Petersen NE, Horder M. Clinically applicable mutation screening in familial hypercholesterolemia. Hum Mutat. 1996; 8: 168–177.
Lombardi P, Sijbrands EJG, Van de Giessen K, Smelt AH, Kastelein JJP, Frants RR, Havekes LM. Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing. J Lipid Res. 1995; 36: 860–867.
Sumner AE, Falker B, Diffenderfer MR, Barrett PHR, Marsh JB. A study of the metabolism of apolipoprotein B100 in relation to insulin resistance in African American males. Proc Soc Exp Biol Med. 1999; 221: 352–360.
Beghin L, Duhal N, Poulain P, Hauw P, Lacroix B, Lecerf JM, Bonte JP, Fruchart JC, Luc G. Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry. J Lipid Res. 2000; 41: 1172–1176.
Havekes LM, de Kniff, Beisegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res. 1987; 28: 455–463.
Okubo K, Ikewaki K, Sakai S, Tada N, Kawaguchi Y, Mochizuki S. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J Am Soc Nephrol. 2004; 15: 1008–1015.
Maugeais C, Ouguerram K, Frenais R, Maugere P, Charbonnel B, Magot T, Krempf M. Effect of low-density lipoprotein apheresis on kinetics of apolipoprotein B in heterozygous familial hypercholesterolemia. J Clin Endocrinol Metab. 2001; 86: 1679–1686.
Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 2003; 52: 803–811.
Stefanovski D, Moate PJ, Boston RC. WinSAAM: a windows-based compartmental modeling system. Metabolism. 2003; 52: 1153–1166.
Lehrman MA, Schneider WJ, Brown MS, Davis CG, Elhammer A, Russell DW, Goldstein JL. The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. J Biol Chem. 1987; 262: 401–410.
Webb JC, Sun XM, McCarthy SN, Neuwirth C, Thompson GR, Knight BL, Soutar AK. Characterization of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolemia, and frequency of these mutations in FH patients in the United Kingdom. J Lipid Res. 1996; 37: 368–381.
Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992; 1: 445–466.
Hobbs HH, Leitersdorf E, Leffert CC, Cryer DR, Brown MS, Goldstein JL. Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective low density lipoprotein receptors. J Clin Invest. 1989; 84: 656–664.
Sun XM, Patel DD, Webb JC, Knight BL, Fan LM, Cai HJ, Soutar AK. Familial hypercholesterolemia in China. Identification of mutations in the LDL-receptor gene that result in a receptor-null phenotype. Arterioscler Thromb. 1994; 14: 85–94.
Deiana L, Garuti R, Pes GM, Carru C, Errigo A, Rolleri M, Pisciotta L, Masturzo P, Cantafora A, Calandra S, Bertolini S. Influence of ?0-thalassemia on the phenotypic expression of heterozygous familial hypercholesterolemia: a study of patients with familial hypercholesterolemia from Sardinia. Arterioscler Thromb Vasc Biol. 2000; 20: 236–243.
Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993; 92: 883–893.
Packard CJ, Boag DE, Clegg R, Bedford D, Shepherd J. Effect of 1,2-cyclohexanedione modification on the metabolism of very low density lipoprotein apolipoprotein B: potential role of receptors in intermediate density lipoprotein catabolism. J Lipid Res. 1985; 26: 1058–1067.
Tremblay AJ, Lamarche B, Ruel IL, Hogue JC, Bergeron J, Gagne C, Couture P. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation. J Lipid Res. 2004; 45: 866–872.
Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973; 70: 2804–2808.
James JH, Soeters PB, Escourrou J, Fischer JE. Decreased cholesterol and fatty acid synthesis following portacaval shunt. Surg Forum. 1977; 28: 397–399.
Cummings MH, Watts GF, Umpleby M, Hennessy TR, Quiney JR, Sonksen PH. Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study. Atherosclerosis. 1995; 113: 79–89.(John S. Millar; Cyrille M)
Correspondence to John S. Millar, PhD, University of Pennsylvania, 644 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104. E-mail jsmillar@mail.med.upenn.edu
Abstract
Objective— We addressed the role of the low-density lipoprotein (LDL) receptor in determining clearance rates and production rate (PR) of apolipoprotein B (apoB) in humans.
Methods and Results— Kinetic studies using endogenous labeling of apoB with deuterated leucine were performed in 7 genetically defined patients with homozygous familial hypercholesterolemia (FH) and compared with 4 controls. The fractional catabolic rates (FCR) and PRs for apoB were determined by multicompartmental modeling. The FCRs of very-low-density lipoprotein 1 (VLDL1), VLDL2, intermediate-density lipoprotein (IDL), and LDL apoB were lower in FH than in controls, with the LDL apoB FCR being significantly lower (0.148±0.049 versus 0.499±0.099 pools · d–1; P=0.008). Whereas receptor-defective FH patients had a total apoB PR similar to controls, receptor-null FH patients had a significantly greater total apoB PR than controls (35.97±10.51 versus 21.32±4.21 mg · kg–1 · d–1, respectively; P=0.02).
Conclusions— This first study of apoB metabolism in homozygous FH using endogenous labeling with stable isotopes demonstrates that the LDL receptor contributes significantly to the clearance of LDL from plasma but plays a lesser role in the clearance of larger apoB-containing lipoproteins. Furthermore, these data also indicate that absence of a LDL receptor in humans substantially influences the apoB PR in vivo.
Kinetic studies on apoB were conducted in genetically defined patients with homozygous FH. FH patients had significantly decreased clearance of LDL apoB. Receptor-null FH had a significantly increased apoB production. We conclude that the LDL receptor primarily mediates clearance of LDL apoB from plasma and can influence apoB production in vivo.
Key Words: cholesterol ? familial hypercholesterolemia ? VLDL ? LDL ? apoB
Introduction
The low-density lipoprotein (LDL) receptor is best known for its role in mediating the hepatic uptake of LDL from plasma.1 Mutations in the LDL receptor frequently result in familial hypercholesterolemia (FH), a disorder associated with hypercholesterolemia and premature atherosclerosis.1 Whereas patients with FH have elevations in LDL cholesterol levels, plasma triglyceride levels are generally normal,1 suggesting that other mechanisms clear the majority of triglyceride-rich very-low-density lipoprotein (VLDL) and VLDL remnants. Previous studies conducted using lipoproteins exogenously labeled with radiotracers have demonstrated a slower fractional catabolic rate (FCR) of intermediate-density lipoprotein (IDL) and LDL apolipoprotein (apoB), but not VLDL apoB, in homozygous FH patients.2,3
In addition to the role of mediating clearance of apoB-containing lipoproteins, a role for the LDL receptor in regulating the hepatic production rate (PR) of VLDL apoB has been proposed.4,5 Williams et al4 observed that blocking LDL receptor on the surface of the HepG2 cells affected apoB secretion. This led them to conclude that there can be reuptake of newly secreted apoB from hepatocytes by the LDL receptor. Twisk et al5 studied apoB secretion in vitro using primary hepatocyte cultures from Ldlr–/– and wild-type mice. They found that hepatocytes from Ldlr–/– mice had reduced intracellular degradation resulting in an increased PR of apoB, which led to their hypothesis that the LDL receptor targets apoB for degradation within the secretory pathway.5
In vivo studies using the Watanabe heritable hyperlipidemic (WHHL) rabbit showed no effect of LDL receptor deficiency on VLDL production.6 However, the WHHL rabbit has defective LDL receptors7 that can potentially influence apoB production.5 We measured apoB production in Ldlr–/– mice and found that despite having a complete absence of LDL receptors, the apoB PR in these animals was similar to wild-type mice.8 Kinetic studies of apoB in homozygous FH patients conducted using radiolabeled lipoproteins have not conclusively established whether deficiency of LDL receptors influences apoB production in humans.2,3
In the current study, we used an endogenous labeling approach with a stable isotope tracer to study the metabolism of apoB in vivo in homozygous FH subjects. The results indicate that in patients lacking a functional LDL receptor, the PR of apoB is significantly increased.
Methods
Subjects
Seven homozygous FH patients were recruited from a cohort followed at the University of Pennsylvania. Four healthy individuals were recruited to act as control subjects. All patients and subjects were nonsmokers with normal hepatic, renal, and thyroid function. Control subjects were not using any medications known to affect plasma lipid levels. FH patients stopped all lipid-lowering treatments 4 weeks before the kinetic studies. The protocol was approved by the Human Investigational Review Board of the University of Pennsylvania. All subjects gave informed consent.
DNA Analysis
Genomic DNA was prepared from peripheral blood leukocytes.9 For denaturing gradient gel electrophoresis analysis,10 the promoter region11 and all 18 exons of the LDL receptor, including the exon–intron boundaries,10,12 were individually amplified from genomic DNA by polymerase chain reaction using TaqDNA polymerase (Qiagen, Germany).
Fragments showing an aberrant pattern of bands, suggestive of a sequence variation, were separately amplified by polymerase chain reaction using the same oligonucleotide primer pairs as used for denaturing gradient gel electrophoresis. The sequence reactions were performed using fluorescently labeled dideoxy chain terminations with the Big Dye Terminator ABI Prism Kit (Applied Biosystems) and analyzed on the Applied Biosystems Model 310 automated DNA sequencer. For confirmation of the sequence variant in other patients, a polymerase chain reaction protocol followed by restriction endonuclease digestion was designed.
Infusion Protocol
Subjects were admitted to the General Clinical Research Center of the Hospital of the University of Pennsylvania. After an overnight fast, subjects consumed the first of 10 bi-hourly solid meals representing one-tenth of the daily caloric intake containing <10% fat. One hour after the first meal, subjects were given a bolus injection (20 μmol · kg–1) of [2H3]-leucine immediately followed by a 12-hour constant infusion of [2H3]-leucine (20 μmol · kg–1 · h–1). Blood samples were drawn periodically for 96 hours after the bolus injection.
Plasma Lipids and Lipoprotein Fraction Preparation
Blood was collected in tubes containing EDTA. Plasma was separated by centrifugation and preservatives added. VLDL1, VLDL2, IDL, and LDL were isolated by ultracentrifugation.13 Plasma total cholesterol, high-density lipoprotein, and triglyceride concentrations were determined using enzymatic reagents (Wako Chemicals USA, Richmond, Va).
Isolation and Quantification of Apolipoproteins
ApoB was isolated from the lipoprotein fractions by isopropanol precipitation, norleucine added as an internal standard, followed by hydrolysis with 6 mol/L HCl at 100°C for 24 hours.14 Under the study dietary conditions there was a negligible contribution of apoB48 (<4%) to the precipitated apoB in the VLDL1 and VLDL2 fractions. ApoE phenotypes were determined on neuraminidase-treated plasma using the method of Havekes et al.15
Determination of Isotopic Enrichment
Free amino acids were isolated from apoB protein hydrolysates by cation exchange chromatography followed by derivatization and determination of tracer/tracee ratio using gas chromatography/mass spectrometry as described.16
Plasma apoB concentrations were measured using an immunoturbidimetric assay (Wako Chemicals USA). The apoB concentration within each lipoprotein fraction was calculated from the apoB leucine content of that fraction, relative to the norleucine internal standard,17 and adjusted to reflect the proportion of total apoB.
Kinetic Analysis
ApoB metabolic parameters (PR and FCR) were calculated from apoB tracer/tracee ratios using 2 independent compartmental models. The first analysis used a previously described model18 with a total VLDL tracer/tracee data set created by taking the weighted mean of the VLDL1 and VLDL2 tracer/tracee data. A confirmatory analysis was conducted19 using the model shown in Figure 1. Both analyses provided similar results. The data included in the manuscript are from the latter analysis. Model calculated pool sizes were within 5% of measured pool size (average of 6 apoB measurements taken over the course of the 96-hour study period).
Figure 1. The multicompartmental model used in the analysis of the deuterated leucine tracer kinetic data.
VLDL1 and VLDL2 kinetic parameters for FH1 were fixed to the average values of the remaining 6 FH patients because of the low concentration of VLDL1, and hence poor tracer data in this subject. Subject C4 had an LDL apoB pool with a rapid turnover (10% of the total LDL pool). To reduce complexity, this portion of the kinetic curve was unweighed.
Statistical Analysis
Statistical comparisons between study groups were made with a Wilcoxon rank sum test. Probability values <0.05 were considered statistically significant.
Results
The subject characteristics at the time of the kinetic study are shown in Table 1. The FH patient group contained 4 males and 3 females and the control group consisted of 2 males and 2 females. All patients and controls displayed an apoE3/3 phenotype. At the time of the kinetic study, the FH patients had significantly higher total cholesterol levels (511±100 versus 128±14 mg · dL–1; P<0.008) and significantly lower high-density lipoprotein cholesterol levels (26±9 versus 42±3 mg · dL–1; P<0.023) than controls, whereas plasma triglyceride levels were similar between the 2 groups (114±74 versus 73±22 mg · dL–; P=0.26). Patient FH6 was hypertriglyceridemic whereas the remaining FH patients were normotriglyceridemic.
TABLE 1. Subject Characteristics at the Time of the Kinetic Study
Representative tracer/tracee ratio curves for the FH and control groups are shown in Figures 2 and 3. The calculated pool sizes within each fraction are shown in Table 2. The VLDL1 and VLDL2 apoB pool sizes in FH patients were similar to controls (1.55±1.95 versus 0.68±0.42 mg · kg–1; P=0.45; 1.80±2.26 versus 0.68±0.22 mg · kg–1; P=0.19, respectively), whereas the IDL and LDL apoB pool sizes were increased in the FH patients (3.85±4.21 versus 1.15±0.25 mg · kg–1; P=0.02; 98.12±16.12 versus 24.79±5.44 mg · kg–1; P<0.001). When the hypertriglyceridemic patient, FH6, was excluded, the VLDL1 apoB pool size was similar to controls (0.83±0.46 versus 0.68±0.42 mg · kg–1; P=0.25), whereas VLDL2, IDL, and LDL apoB pool sizes were significantly larger than those of the controls (0.96±0.31 versus 0.68±0.22 mg · kg–1; P=0.02; 2.27±0.62 versus 1.15±0.25 mg · kg–1; P=0.02; 98.94±17.5 versus 24.79±5.44 mg · kg–1; P<0.02, respectively). Please see http://atvb.ahajournals.org for the apoB concentrations of each fraction.
Figure 2. Representative tracer kinetic data for the VLDL1 and VLDL2 lipoprotein fractions in control subject C3 and FH patient FH7. The model-derived fit to the data (solid triangles) is shown as a solid line.
Figure 3. Representative tracer kinetic data for the IDL and LDL lipoprotein fractions in control subject C3 and FH patient FH7. The model-derived fit to the data (solid triangles) is shown as a solid line.
TABLE 2. Calculated apoB Pool Size and FCR for Each Lipoprotein Fraction
The FCRs for apoB within each lipoprotein fraction are shown in Table 2. As expected, the FCR of LDL apoB was markedly slower in the FH patients compared with the controls (0.148±0.049 versus 0.499±0.099 pools · d–1; P=0.008). Although not significant, the FH patients also had slower FCRs for VLDL1 (7.02±2.78 versus 10.29±4.92 pools · d–1; P=0.19), VLDL2 (12.64±7.19 versus 16.94±5.98 pools · d–1; P=0.57), and IDL (9.56±9.10 versus 12.17±1.92 pools · d–1; P=0.26) apoB.
There were no significant differences between FH patients and controls in the direct PRs of VLDL1, VLDL2, IDL, or LDL apoB (Table 3). There were also no significant differences in the total PRs (direct hepatic production plus conversion from other fractions) of apoB in any lipoprotein fraction or conversion rates of apoB between lipoprotein fractions. There was a nonsignificant trend toward an increased total apoB PR in FH patients compared with controls (32.11±10.44 versus 21.32±4.21 mg · kg–1 · d–1; P=0.06).
TABLE 3. Production and Conversion Rates of apoB From Each Lipoprotein Fraction
Three of the FH patients were receptor-defective and therefore expressed partially functional LDL receptor. A subgroup analysis was conducted in the 4 LDL receptor-null patients with the FH Lebanese mutation (C660X). This mutation produces a truncated receptor that is not fully processed and is degraded before reaching the cell surface,20 resulting in a LDL receptor-null phenotype. A subanalysis comparing receptor-null FH patients to controls showed that these patients had significantly increased total VLDL2 and IDL apoB PRs than control subjects (20.42±6.44 versus 12.10±1.56 mg · kg–1 · d–1; P=0.02; 21.44±8.21 versus 13.69±1.51 mg · kg–1 · d–1; P=0.04, respectively) and greater total apoB PRs than controls (35.97±10.51 versus 21.32±4.21 mg · kg–1 · d–1; P=0.02). FH patients that have expression of partially functional LDL receptors or low-level expression of fully functional LDL receptors had total apoB PRs that were similar to controls (25.85±7.72 versus 21.32±4.21 mg · kg–1 · d–1, receptor-defective FH versus control, respectively, P=0.48).
Discussion
This report of apoB kinetics using endogenous labeling with stable isotopes confirms that LDL apoB clearance is markedly decreased in homozygous FH patients. It also establishes that homozygous FH patients with mutations resulting in a complete absence of the LDL receptor have an increased apoB PR, supporting predictions based on in vitro studies.
An important aspect of this study is that all FH patients were characterized for their LDL receptor mutations at the molecular level. Three of the 7 FH patients (FH1 to FH3) had receptor-defective mutations that either resulted in reduced levels of functional receptor (FH1)21,22 or affected ligand binding (FH2, FH3).23–25 Four patients (FH4-FH7) were homozygous for the FH Lebanese mutation.20 This mutation results in transcription of a truncated receptor that not fully processed and is retained in the endoplasmic reticulum (ER),20 resulting in a receptor-null phenotype.
Although FH patients have elevated total cholesterol levels, plasma triglyceride levels are frequently normal suggesting less of a role for the LDL receptor in the clearance of triglyceride-rich lipoproteins. Although VLDL clearance can be enhanced in Ldlr–/– mice through overexpression of the LDL receptor,26 the extent to which VLDL and IDL apoB are cleared from plasma by LDL receptors in vivo in humans is not established. Packard et al27 found that modification of the LDL receptor binding region of apoB had no effect on VLDL clearance but reduced clearance of IDL in normal subjects. Using radiolabeled lipoproteins, James et al2 found VLDL1 and VLDL2 clearance in homozygous FH to be similar to control subjects whereas the FCR of IDL apoB was significantly slower than controls. Soutar et al3 also observed slower clearance of IDL apoB in homozygous FH. In the current study, using endogenous labeling, we observed slower, but not significant, clearance of IDL apoB in FH patients. The FCRs of VLDL1 and VLDL2 apoB were not significantly different between FH patients and controls indicating a minor role of the LDL receptor in the clearance of these lipoproteins.
The role of the LDL receptor in regulating apoB production was first highlighted in in vitro studies by Williams et al.4 They noted an increased secretion of apoB from hepatocytes in which the LDL receptor was blocked to prevent lipoprotein uptake. Twisk et al5 found increased secretion of apoB by primary hepatocytes from Ldlr–/– mice when compared with wild-type mice. Analysis of the tracer data suggested that this was caused by reduced presecretory degradation of apoB and reduced capture of newly secreted VLDL. This led to their hypothesis that the LDL receptor may bind apoB intracellularly and target it for degradation. In vivo studies in the WHHL rabbit6 and Ldlr–/– mice8 showed no differences in the PR of VLDL triglyceride or apoB when compared with Ldlr+/+ control animals. Whereas the WHHL rabbit is considered receptor-defective and may be capable of targeting newly synthesized apoB for degradation, the same cannot be said for Ldlr–/– mice that are receptor-null. The discrepancy observed between in vivo and in vitro studies in mice may be caused by differential changes in expression of genes involved in VLDL secretion by wild-type and Ldlr–/– primary hepatocytes after several hours in culture, although this remains to be tested.
Human kinetic studies using exogenously radiolabeled lipoproteins in patients with homozygous FH have not shown consistent differences with control subjects in the apoB PR.2,3 A report by Soutar et al3 found that VLDL apoB PRs among uncharacterized FH homozygotes, heterozygotes, and normal control subjects were similar. Subsequently, James et al2 reported that homozygous FH patients had significantly greater (>60%) apoB PRs as compared with control subjects. Despite this increased PR in the total group of FH homozygotes, those patients with <10% LDL receptor activity had total apoB PRs that were similar to those for control subjects. In the current study, we used endogenous labeling of apoB and also characterized the precise molecular defects in the LDL receptor gene. We found that the total apoB PR in the homozygous FH patients trended higher than control subjects but was not statistically significant. A subgroup analysis comparing patients with an LDL receptor-null phenotype and control subjects demonstrated that the apoB PR was significantly elevated in the receptor-null FH patients. One receptor-null patient (FH6) had elevated plasma triglyceride levels that could potentially result from increased VLDL production. The kinetic analysis revealed that the raised plasma triglyceride level was primarily caused by reduced clearance of VLDL apoB. Despite the metabolic heterogeneity of this receptor-null subgroup, the overall elevated PR measured is consistent with the increased PR measured by Tremblay et al28 in a single receptor-null homozygote. This result supports a role for the LDL receptor in regulating the presecretory degradation of apoB in vivo in humans.
An alternative explanation for increased apoB production in receptor-null FH patients is unregulated hepatic lipid synthesis resulting from the lack of exogenous cholesterol uptake.29 Homozygous FH patients with a portacaval shunt have a relatively low total apoB PR.2 Portacaval shunting has been reported to reduce hepatic lipid synthesis30 and therefore support this alternative explanation. Unregulated hepatic lipid synthesis could also explain the increased apoB production observed in some studies in heterozygous FH.28,31 A recent report indicates that heterozygous FH patients with a receptor-null allele have been shown to have increased apoB production.28 Further studies in FH patients with other receptor-null mutations would be required to determine whether this is a generalized or mutation-specific effect.
In summary, this first study of apoB metabolism in a group of genetically defined homozygous FH patients confirmed a major role for the LDL receptor in the clearance of LDL, but not VLDL or IDL. More importantly, the total apoB PR was significantly increased in receptor-null FH homozygotes. These studies indicate that the LDL receptor plays a major role in the clearance of cholesterol-rich apoB-containing lipoproteins and may also function in modulating the PR of apoB in vivo in humans.
Acknowledgments
Supported by grant M01-RR00040 from the National Center for Research Resources to the University of Pennsylvania General Clinical Research Center, NRSA HL-10365 (J.S.M.), and funds from Genovo, Inc. D.J.R. is a recipient of a Doris Duke Distinguished Clinical Investigator Award. P.H.R.B. is a fellow of the National Health and Medical Research Council of Australia and is partly supported by NIH/NIBIB grant P41 EB-009175. We thank Anna DiFlorio and Linda Morrell for lipid analyses and the nursing staff of the General Clinical Research Center for their assistance. We also thank the patients whose participation and cooperation made these studies possible.
References
Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beauder AL, Sly WS, Valle D, eds The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill; 1995: 1981–2030.
James RW, Martin B, Pometta D, Fruchart JC, Duriez P, Puchois P, Farriaux JP, Tacquet A, Demant T, Clegg RJ. el al. Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res. 1989; 30: 159–169.
Soutar AK, Myant NB, Thompson GR. The metabolism of very low density and intermediate density lipoproteins in patients with familial hypercholesterolaemia. Atherosclerosis. 1982; 43: 217–231.
Williams KJ, Brocia RW, Fisher EA. The unstirred water layer as a site of control of apolipoprotein B secretion. J Biol Chem. 1990; 265: 16741–16744.
Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PHR, Attie AD. The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest. 2000; 105: 521–532.
Hornick CA, Kita T, Hamilton RL, Kane JP, Havel RJ. Secretion of lipoprotein from the liver of normal and Watanabe heritable hyperlipidemic rabbits. Proc Natl Acad Sci, U S A. 1983; 80: 6096–6100.
Yamamoto T, Bishop RW, Brown MS, Goldstein JL, Russell DW. Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. Science. 1986; 1232: 1230–1237.
Millar JS, Maugeais C, Fuki IV, Rader DJ. Normal production rate of apoB in LDL receptor deficient mice. Arterioscler Thromb Vasc Biol. 2002; 22: 989–994.
Mullenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet. 1989; 5: 391.
Khoo KL, Van Acker P, Defesche JC, Tan H, Van de Kerkhof L, Heijnen-van Eijk SJ, Kastelein JJP, Deslypere JP. Low-density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia. Clin Genet. 2000; 58: 98–105.
Nissen H, Guldberg P, Hansen AB, Petersen NE, Horder M. Clinically applicable mutation screening in familial hypercholesterolemia. Hum Mutat. 1996; 8: 168–177.
Lombardi P, Sijbrands EJG, Van de Giessen K, Smelt AH, Kastelein JJP, Frants RR, Havekes LM. Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing. J Lipid Res. 1995; 36: 860–867.
Sumner AE, Falker B, Diffenderfer MR, Barrett PHR, Marsh JB. A study of the metabolism of apolipoprotein B100 in relation to insulin resistance in African American males. Proc Soc Exp Biol Med. 1999; 221: 352–360.
Beghin L, Duhal N, Poulain P, Hauw P, Lacroix B, Lecerf JM, Bonte JP, Fruchart JC, Luc G. Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry. J Lipid Res. 2000; 41: 1172–1176.
Havekes LM, de Kniff, Beisegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res. 1987; 28: 455–463.
Okubo K, Ikewaki K, Sakai S, Tada N, Kawaguchi Y, Mochizuki S. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J Am Soc Nephrol. 2004; 15: 1008–1015.
Maugeais C, Ouguerram K, Frenais R, Maugere P, Charbonnel B, Magot T, Krempf M. Effect of low-density lipoprotein apheresis on kinetics of apolipoprotein B in heterozygous familial hypercholesterolemia. J Clin Endocrinol Metab. 2001; 86: 1679–1686.
Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 2003; 52: 803–811.
Stefanovski D, Moate PJ, Boston RC. WinSAAM: a windows-based compartmental modeling system. Metabolism. 2003; 52: 1153–1166.
Lehrman MA, Schneider WJ, Brown MS, Davis CG, Elhammer A, Russell DW, Goldstein JL. The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. J Biol Chem. 1987; 262: 401–410.
Webb JC, Sun XM, McCarthy SN, Neuwirth C, Thompson GR, Knight BL, Soutar AK. Characterization of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolemia, and frequency of these mutations in FH patients in the United Kingdom. J Lipid Res. 1996; 37: 368–381.
Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992; 1: 445–466.
Hobbs HH, Leitersdorf E, Leffert CC, Cryer DR, Brown MS, Goldstein JL. Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective low density lipoprotein receptors. J Clin Invest. 1989; 84: 656–664.
Sun XM, Patel DD, Webb JC, Knight BL, Fan LM, Cai HJ, Soutar AK. Familial hypercholesterolemia in China. Identification of mutations in the LDL-receptor gene that result in a receptor-null phenotype. Arterioscler Thromb. 1994; 14: 85–94.
Deiana L, Garuti R, Pes GM, Carru C, Errigo A, Rolleri M, Pisciotta L, Masturzo P, Cantafora A, Calandra S, Bertolini S. Influence of ?0-thalassemia on the phenotypic expression of heterozygous familial hypercholesterolemia: a study of patients with familial hypercholesterolemia from Sardinia. Arterioscler Thromb Vasc Biol. 2000; 20: 236–243.
Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993; 92: 883–893.
Packard CJ, Boag DE, Clegg R, Bedford D, Shepherd J. Effect of 1,2-cyclohexanedione modification on the metabolism of very low density lipoprotein apolipoprotein B: potential role of receptors in intermediate density lipoprotein catabolism. J Lipid Res. 1985; 26: 1058–1067.
Tremblay AJ, Lamarche B, Ruel IL, Hogue JC, Bergeron J, Gagne C, Couture P. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation. J Lipid Res. 2004; 45: 866–872.
Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973; 70: 2804–2808.
James JH, Soeters PB, Escourrou J, Fischer JE. Decreased cholesterol and fatty acid synthesis following portacaval shunt. Surg Forum. 1977; 28: 397–399.
Cummings MH, Watts GF, Umpleby M, Hennessy TR, Quiney JR, Sonksen PH. Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study. Atherosclerosis. 1995; 113: 79–89.(John S. Millar; Cyrille M)